Drugs | Trial/Phase | Setting | Population | ORR n/N (%) | DCR n/N (%) | PFS (mo = months) | OS (mo = months) |
---|---|---|---|---|---|---|---|
Pembrolizumab [17] | NCT01876511 Phase II | > 2 L | MSI-H/dMMR | 21/41 (52) | 33/40 (82) | 2-year = 59% mPFS NR | 2-year = 85% mOS NR |
KEYNOTE-164 Phase II | > 2 L | MSI-H/dMMR | 21/63 (33) | 36/63 (57) | 12-mo = 41% mPFS 4.1 mo (2.1 – NR) | 12-mo = 76% mOS NR (19.2 – NR) | |
> 3 L | MSI-H/dMMR | 17/61 (28) | 31/61 (51) | 12-mo = 34% mPFS 2.3 mo (2.1–8.1) | 12-mo = 72% mOS NR | ||
Pembrolizumab + mFOLFOX6 [20] | NCT02375672 Phase II | 1 L | MSI-unselected | 12/30 (40) | 23/30 (77) | PFS not reported mPFS 16.9 mo (7.4, 16.9) | OS not reported mOS 8.8 mo (18.3-NE) |
Nivolumab [21] | CheckMate 142 Phase II | > 2 L | MSI-H/dMMR | 23/74 (31) | 51/74 (69) | 12-mo = 50% mPFS 14.3 mo (4.3, NE) | 12-mo = 73% mOS, NR (18.0, NE) |
Nivolumab + low dose Ipilimumab [22] | ChackMate 142 Phase II | > 2 L | MSI-H/dMMR | 65/119 (55) | 95/119 (80) | 12-mo = 71% mPFS NR | 12-mo = 85% mOS NR |
Atezolizumab + bevacizumab and fluoropyrimidine [23] | NCT02291289 Phase II | 1 L (maintenance) | MSI-unselected | Not reported | Not reported | mPFS 7.2 mo | mOS 22.1 mo |
Atezolizumab + FOLFOX + bevacizumab [24] | NCT01633970 Phase Ib | > 2 L | Oxaliplatin naïve | 9/25 (31) | Not reported | Not reported | Not reported |
Atezolizumab + bevacizumab [25] | NCT01633970 Phase I | > 2 L | MSI-H/dMMR | 4/10 (40) | 9/10 (90) | mPFS NR (1.5–21.9) | mOS NR (2.6–23.7) |